Share
When families hear about a dramatic response to immunotherapy, they understandably ask: “Why can’t we use the same medicine?” Immunotherapy has changed treatment in several cancers, sometimes producing long-lasting benefit. It is not, however, a universal stronger treatment for every cancer.
The answer depends on the cancer, its stage and biology, the particular medicine and the person receiving it. Not responding does not mean that the patient failed to stay positive or simply has weak immunity. It is a treatment–cancer interaction, not a test of willpower.
Which immunotherapy are we discussing?
This article mainly concerns immune checkpoint inhibitors, medicines that target pathways such as PD-1, PD-L1 or CTLA-4. They differ from CAR-T cell therapy, other cell therapies, therapeutic vaccines and antibodies with other mechanisms. Eligibility, evidence and risks are not interchangeable.
Ask for the exact medicine name. “Immunotherapy” alone is not enough to assess a recommendation, estimate benefit or compare alternatives.
How do checkpoint inhibitors work?
The immune system needs to recognise threats without continually attacking healthy tissue. Checkpoints help control that balance. Some cancers exploit inhibitory signals to reduce immune-cell activity. Blocking an appropriate signal can permit an anticancer immune response.
One way to picture it is a security response being restrained. Releasing the restraint can help, but only if the problem can be recognised and reached. It does not automatically overcome every mechanism the cancer uses to escape.
That also explains toxicity: increased immune activity can affect healthy organs. Immunotherapy does not exclusively target cancer while leaving every normal cell untouched.
Why are some tumours more responsive?
Cancers differ in their abnormal proteins, immune-cell populations and surrounding signals. Some are more visible to the immune system; others are poorly recognised or suppress effective immune activity. Differences occur both between cancer types and within the same named disease.
The treatment setting matters. Results in metastatic cancer do not automatically apply before surgery or after complete removal. A medicine may be useful in a combination but insufficient alone in that setting.
The practical question is: “What evidence supports this exact regimen for my diagnosis and stage?” That is more informative than whether the drug is described as modern.
What do biomarkers tell us?
There is no single test predicting every patient’s response. Different cancers use different assays, thresholds and treatment rules.
If the table extends beyond your screen, swipe or scroll sideways to read every column.
Biomarker | What it assesses | Important qualification |
|---|---|---|
PD-L1 | Expression of an immune-checkpoint-related protein | A high result does not guarantee benefit; a low result does not exclude every immunotherapy regimen. |
dMMR / MSI-high | A pattern associated with faulty DNA repair | Can strongly influence treatment in several cancers, but the clinical setting still matters. |
Tumour mutational burden (TMB) | An estimate of the number of tumour DNA changes | Has a role in selected contexts; it is not a universal response score. |
PD-L1 may be reported as a tumour proportion score or combined positive score. They are not interchangeable percentages. Do not compare your result with another patient’s without checking the cancer, assay and scoring method.
Ask what the result changes: one drug, a combination, a different sequence or no change at all.
Can immunotherapy work with a negative PD-L1 result?
Sometimes. Evidence supports immunotherapy-containing combinations without PD-L1 selection in some settings, while other uses depend on the result. The rules belong to the particular cancer and regimen.
Conversely, positivity does not always make immunotherapy alone the preferred option. Symptoms, disease tempo, other molecular results and evidence for competing treatments may change the recommendation.
A biomarker is therefore a decision aid, not a prescription in isolation.
Why might targeted therapy be chosen instead?
Some cancers have molecular alterations for which a targeted medicine is particularly effective. In an appropriate treatment setting, the evidence may favour that approach rather than immunotherapy. This is one reason relevant biomarker results can matter before the first treatment is chosen, when waiting is clinically safe.
Personalised treatment means selecting the most appropriate plan, not necessarily using more drugs or the most fashionable category.
Why combine immunotherapy with other treatments?
Chemotherapy, targeted medicines or another immune treatment may act in complementary ways. A trial may establish benefit for a particular combination. The added toxicity and contribution of each component still need discussion.
Adding immunotherapy to any chemotherapy is not automatically beneficial. Nor is a two-immunotherapy combination necessarily better than one medicine for every patient.
Ask what the combination adds compared with the main alternative, how benefit was measured and which extra risks matter. Clarify what happens if one component needs to be held or stopped.
What other health issues influence suitability?
Tell the team about autoimmune disease, organ transplantation, previous severe immune reactions, infections and immune-suppressing medicines. These situations have different implications but can substantially affect risk and specialist input. Do not stop prescribed steroids or other medicines independently.
The ability to obtain monitoring and urgent advice matters too. A treatment requiring prompt recognition of inflammation needs a workable safety plan, not simply an infusion slot.
How quickly will we know whether it helps?
Doctors combine symptoms, examination and appropriately timed imaging; selected markers may add information. There is no universal rule that a response must appear after one or two doses. Equally, treatment should not continue indefinitely without evidence of benefit.
A small minority of patients have apparent early scan progression followed by response, called pseudoprogression. Most worsening is not automatically explained this way. A deteriorating patient needs assessment, not reassurance that immunotherapy merely takes time.
Agree on a reassessment plan and what findings would prompt continuation, a hold or a change.
Why can an initial response stop?
Some cancers resist immunotherapy from the beginning; others change and escape control later. Researchers are studying several mechanisms of resistance, but switching to another similar drug is not automatically effective.
If progression occurs, the team may reconsider the diagnosis, molecular findings, alternative systemic treatments, a local treatment for selected disease sites or a clinical trial. A medicine that once helped does not necessarily remain the best option forever.
Can supplements make immunotherapy work better?
Nutrition, appropriate activity and general healthcare support the patient. That differs from proving that an “immune booster” improves immunotherapy’s anticancer effect. Supplements can interact with medicines or cause harm. Share product names and ingredients with the oncology pharmacist.
There is no reason to blame a poor response on a food choice, distress or inability to remain optimistic. Treatment decisions should follow evidence rather than claims attached to an immunity label.
How should I judge claims about dramatic results?
Ask which cancer and treatment setting were studied, what treatment was compared, how many patients benefited and for how long. A complete response in a small group does not automatically predict the same outcome for a different disease.
Separate published evidence from regulatory approval, guideline support and availability. A conference presentation can be important but may be preliminary. An overseas approval does not automatically establish routine treatment access in India.
A balanced explanation should discuss limitations without dismissing genuine advances. Hope and accurate information are not opposites.
Frequently asked questions
Is immunotherapy only used for stage 4 cancer?
No. It has roles in some earlier-stage cancers as well, depending on the disease and regimen. It is not governed by one stage-based rule.
Does having no side effects mean it is not working?
No. Toxicity is not a reliable measure of an individual’s response. Do not hope for or tolerate an immune complication to prove benefit.
Can I stop after a clear scan?
Discuss it with the team. Some regimens have defined durations; others depend on benefit and tolerability. A complete response does not automatically settle how long treatment should continue.
Can immunotherapy replace chemotherapy in every cancer?
No. Sometimes it is preferred, sometimes chemotherapy remains essential, and sometimes the evidence favours a combination. The recommendation should be cancer-specific.
The useful question is not whether immunotherapy is good in general. It is what makes it appropriate—or inappropriate—for your cancer now.
Medical information notice: This information is for general education and does not replace individual medical advice. Cancer treatment depends on the diagnosis, stage, tumour biology, previous treatment, general health and individual circumstances.
